Volume 139, Issue 2, Pages 491-498 (August 2010) Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B  Jurriën G.P. Reijnders, Moniek J. Perquin, Ningping Zhang, Bettina E. Hansen, Harry L.A. Janssen  Gastroenterology  Volume 139, Issue 2, Pages 491-498 (August 2010) DOI: 10.1053/j.gastro.2010.03.059 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Kaplan–Meier curve for the cumulative probabilities of achieving HBeAg seroconversion during nucleos(t)ide analogue therapy. (A) Number of patients who have not achieved HBeAg seroconversion and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have achieved HBeAg seroconversion. Gastroenterology 2010 139, 491-498DOI: (10.1053/j.gastro.2010.03.059) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Kaplan–Meier curve for the cumulative probabilities of developing serologic recurrence, defined as reappearance of HBeAg confirmed by HBeAg positivity in a consecutive sample, after HBeAg seroconversion. (A) Number of patients who have not developed serologic recurrence and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have developed serologic recurrence. Gastroenterology 2010 139, 491-498DOI: (10.1053/j.gastro.2010.03.059) Copyright © 2010 AGA Institute Terms and Conditions

Figure 3 Kaplan–Meier curve for the cumulative probabilities of developing virologic recurrence, defined as an increase of HBV DNA to greater than 10,000 copies/mL after HBeAg seroconversion and previously having been less than 10,000 copies/mL, confirmed in a consecutive sample. (A) Number of patients who have not developed virologic recurrence and are still in follow-up evaluation. (B) Number of patients who are still in follow-up evaluation, whether or not they have developed virologic recurrence. Eight patients had ongoing viral replication with HBV-DNA levels greater than 10,000 copies/mL despite the achievement of HBeAg seroconversion and were excluded from this analysis. Gastroenterology 2010 139, 491-498DOI: (10.1053/j.gastro.2010.03.059) Copyright © 2010 AGA Institute Terms and Conditions

Figure 4 Proportion of patients who developed serologic and/or virologic recurrence after nucleos(t)ide analogue-induced HBeAg seroconversion, and causes of serologic and/or virologic recurrence, specified per treatment regimen. Gastroenterology 2010 139, 491-498DOI: (10.1053/j.gastro.2010.03.059) Copyright © 2010 AGA Institute Terms and Conditions